1342.2 Evaluation Webform

­­­­­­­Activity Evaluation Form and Application for Continuing Medical Education Credit

Best Practices for Incorporating Janus Kinase Inhibitors Into the Treatment of Rheumatoid Arthritis

We greatly value your opinion. Your responses in this evaluation will be used in future planning of new courses and offerings for members of the healthcare team.

Click on the “Submit” button when you have finished the evaluation and the “Next” button to obtain your certificate.

MD DO PharmD RN NP PA Other
I am a:
Strongly Agree Agree Disagree Strongly Disagree
Discuss important efficacy and safety data of current and emerging Janus kinase (JAK) inhibitors used in the treatment of rheumatoid arthritis (RA)
Describe how JAK inhibitors may be integrated into evidence-based guidelines for the treatment of RA
Apply best evidence regarding the optimal use of JAK inhibitors to design ideal treatment plans for patients with RA

Please indicate the extent of your agreement with the following statements:

Most Valuable Valuable Somewhat Valuable Least Valuable
This CME activity
Direct to consumer advertising
Sales representative visits
Promotional/other non-certified education